Cargando…
A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer
PURPOSE: The study aimed to explore whether the expression of lncRNAs in primary tumors could predict nodal efficacy after neoadjuvant therapy (NAT) for HER2+ breast cancer. METHODS: Total RNA was extracted from HER2+ breast cancer tissues before NAT (n=103) and from 48 pairs of cancers and para-can...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685269/ https://www.ncbi.nlm.nih.gov/pubmed/34938660 http://dx.doi.org/10.3389/fonc.2021.779140 |
_version_ | 1784617798036619264 |
---|---|
author | Bi, Zhao Qiu, Peng-Fei Zhang, Yue Song, Xing-Guo Chen, Peng Xie, Li Wang, Yong-Sheng Song, Xian-Rang |
author_facet | Bi, Zhao Qiu, Peng-Fei Zhang, Yue Song, Xing-Guo Chen, Peng Xie, Li Wang, Yong-Sheng Song, Xian-Rang |
author_sort | Bi, Zhao |
collection | PubMed |
description | PURPOSE: The study aimed to explore whether the expression of lncRNAs in primary tumors could predict nodal efficacy after neoadjuvant therapy (NAT) for HER2+ breast cancer. METHODS: Total RNA was extracted from HER2+ breast cancer tissues before NAT (n=103) and from 48 pairs of cancers and para-cancers tissues that did not receive NAT. Different lncRNAs were selected by microarray, validated by qPCR, and analyzed to illuminate their potential as nodal efficacy biomarkers after NAT. RESULTS: Our results demonstrated that three lncRNA sets, lncRNA-AL390243.1, POTEH-AS1, and lncRNA-AC009975.1, were up-regulated in non-apCR tissues. The AUC value was 0.789 (95%CI: 0.703-0.876). The multivariate logistic regression analysis identified the expression of lncRNA-AL390243.1 (OR 5.143; 95% CI: 1.570-16.847), tumor type (OR 0.144; 95% CI: 0.024-0.855), and nodal stage (OR 0.507; 95% CI: 0.289-0.888) as independent predictors for apCR after NAT in HER2+ patients (all p<0.05). Then the three predictors were used to create a predictive nomogram. The AUC value was 0.859 (95%CI: 0.790-0.929). The calibration curve showed a satisfactory fit between predictive and actual observation based on internal validation with a bootstrap resampling frequency of 1000. Patients with higher expression of lncRNA-AL390243.1 had worse survival. LncRNA-AL390243.1 was up-regulated more in the nodal positive subgroup than in the nodal negative subgroup (p=0.0271). CONCLUSION: The lncRNA-AL390243.1, POTEH-AS1, and lncRNA-AC009975.1 were upregulated in non-apCR breast cancer tissues. These three lncRNAs might have the potential to be used as predictive biomarkers of nodal efficacy of HER2+ breast cancer. Further studies are required to illuminate the underlying molecular mechanisms further. |
format | Online Article Text |
id | pubmed-8685269 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86852692021-12-21 A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer Bi, Zhao Qiu, Peng-Fei Zhang, Yue Song, Xing-Guo Chen, Peng Xie, Li Wang, Yong-Sheng Song, Xian-Rang Front Oncol Oncology PURPOSE: The study aimed to explore whether the expression of lncRNAs in primary tumors could predict nodal efficacy after neoadjuvant therapy (NAT) for HER2+ breast cancer. METHODS: Total RNA was extracted from HER2+ breast cancer tissues before NAT (n=103) and from 48 pairs of cancers and para-cancers tissues that did not receive NAT. Different lncRNAs were selected by microarray, validated by qPCR, and analyzed to illuminate their potential as nodal efficacy biomarkers after NAT. RESULTS: Our results demonstrated that three lncRNA sets, lncRNA-AL390243.1, POTEH-AS1, and lncRNA-AC009975.1, were up-regulated in non-apCR tissues. The AUC value was 0.789 (95%CI: 0.703-0.876). The multivariate logistic regression analysis identified the expression of lncRNA-AL390243.1 (OR 5.143; 95% CI: 1.570-16.847), tumor type (OR 0.144; 95% CI: 0.024-0.855), and nodal stage (OR 0.507; 95% CI: 0.289-0.888) as independent predictors for apCR after NAT in HER2+ patients (all p<0.05). Then the three predictors were used to create a predictive nomogram. The AUC value was 0.859 (95%CI: 0.790-0.929). The calibration curve showed a satisfactory fit between predictive and actual observation based on internal validation with a bootstrap resampling frequency of 1000. Patients with higher expression of lncRNA-AL390243.1 had worse survival. LncRNA-AL390243.1 was up-regulated more in the nodal positive subgroup than in the nodal negative subgroup (p=0.0271). CONCLUSION: The lncRNA-AL390243.1, POTEH-AS1, and lncRNA-AC009975.1 were upregulated in non-apCR breast cancer tissues. These three lncRNAs might have the potential to be used as predictive biomarkers of nodal efficacy of HER2+ breast cancer. Further studies are required to illuminate the underlying molecular mechanisms further. Frontiers Media S.A. 2021-12-06 /pmc/articles/PMC8685269/ /pubmed/34938660 http://dx.doi.org/10.3389/fonc.2021.779140 Text en Copyright © 2021 Bi, Qiu, Zhang, Song, Chen, Xie, Wang and Song https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Bi, Zhao Qiu, Peng-Fei Zhang, Yue Song, Xing-Guo Chen, Peng Xie, Li Wang, Yong-Sheng Song, Xian-Rang A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer |
title | A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer |
title_full | A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer |
title_fullStr | A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer |
title_full_unstemmed | A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer |
title_short | A Three lncRNA Set: AC009975.1, POTEH-AS1 and AL390243.1 as Nodal Efficacy Biomarker of Neoadjuvant Therapy for HER-2 Positive Breast Cancer |
title_sort | three lncrna set: ac009975.1, poteh-as1 and al390243.1 as nodal efficacy biomarker of neoadjuvant therapy for her-2 positive breast cancer |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8685269/ https://www.ncbi.nlm.nih.gov/pubmed/34938660 http://dx.doi.org/10.3389/fonc.2021.779140 |
work_keys_str_mv | AT bizhao athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT qiupengfei athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT zhangyue athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT songxingguo athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT chenpeng athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT xieli athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT wangyongsheng athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT songxianrang athreelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT bizhao threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT qiupengfei threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT zhangyue threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT songxingguo threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT chenpeng threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT xieli threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT wangyongsheng threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer AT songxianrang threelncrnasetac0099751potehas1andal3902431asnodalefficacybiomarkerofneoadjuvanttherapyforher2positivebreastcancer |